BioMoti ^Companies

BioMoti is an organization that aims to revolutionize cancer treatment by delivering therapeutics directly to cancer cells. Their goal is to increase the effectiveness of treatment while minimizing side effects. They have developed a new class of therapeutic microparticles called Oncojans™, which target and enter the interior of cancer cells to release drugs at the point of need. This platform is compatible with various types of drugs, from small molecules to larger biologicals. Their lead candidate, MOTI1001, has shown promising potential in early preclinical studies for ovarian cancer.